Background: Mesenchymal stem cells (MSC) are easily harvested, and possess antiinflammatory and trophic properties. Furthermore, MSC promote neuroprotection and neurogenesis, which could greatly benefit neurodegenerative disorders, such as Parkinson's disease. Methods: MSC were transplanted one week after 6-hydroxydopamine lesioning and effects were evaluated after 6 months. Results: MSC localized around the substantia nigra and the arachnoid mater, expressing pericyte and endothelial markers. MSC protected dopamine levels and upregulated peripheral antiinflammatory cytokines. Furthermore, adipose-derived MSC increased neurogenesis in hippocampal and subventricular regions, and boosted memory functioning. Conclusion: Considering that hyposmia and loss of memory function are two major nonmotor symptoms in Parkinson's disease, transplants with modulatory effects on the hippocampus and subventricular zone could provide a disease-modifying therapy.
Parkinson's disease (PD) affects approximately 1% of the population over 60 years of age, making it the most common neurodegenerative movement disorder [1] . The hallmark of the disease consists in the progressive degeneration of dopaminergic neurons in the substantia nigra (SN) and α-synucleinpositive inclusions in cell bodies and neurites (Lewy bodies) of nigral and olfactory bulb (OB) neurons [2, 3] . These degenerative processes go together with decreased neurogenesis in the subgranular zone (SGZ) and the subventricular zone (SVZ) -OB axis [4, 5] . Furthermore, neurodegeneration in PD has been linked to hyposmia and disease-related cognitive decline [6] [7] [8] , which are two major nonmotor symptoms related with the majority of PD patients. The decreases in neurogenesis that occur in both neurogenic zones have been attributed to the degeneration of the dopaminergic innervations [4] , as demonstrated by several experimental evidences throughout PD models [9] . This suggests that the modulation of endogenous neuronal plasticity in the SVZ-OB axis and in the hippocampus could be a potential regenerative therapeutic target for PD. Many recent studies were built, exploring strategies by either restoring dopaminergic neurons or through the modulation of the proinflammatory microenvironment, which is a part of the pathogenesis in PD [10] . In line with the latter strategy, infused growth factors like GDNF and VEGF [11] , and factors counteracting oxidative stress -like erythropoietin (EPO) [12] -showed regenerative and neurogenic effects in PD models. Similarly, other studies transplanted immunomodulatory adult mesenchymal stem cells (MSC) [13] that can naturally secrete trophic factors and cytokines which are important not only for proand anti-inflammatory modulation [14, 15] but also for the generation and differentiation of newborn neurons in neurogenic regions of the adult brain. In contrast with embryonic or induced-pluripotent stem cells (ipSC), MSC are immunosuppressive and among others have a nontumorigenic potential Adipose-derived human mesenchymal stem cells induce long-term neurogenic and anti-inflammatory effects and improve cognitive but not motor performance in a rat model of Parkinson's disease future science group Research Article Schwerk, Altschüler, Roch et al. upon transplantation [16] and are free of ethical constraints. In addition to their immunosuppressive and trophic properties, MSC are able to home toward the regions of injury [17] , which enables them to function as a targeted delivery of trophic factors and cytokines. Given the increase in proinflammatory cytokines and the severe depletion of neurotrophins in PD [18, 19] , trophic factor secreting MSC could support endogenous repair systems. This was shown in a study conducted in 6-hydroxydopamine (6-OHDA) lesioned rats [20] and Parkinsonian mice [21] , whose adult subventricular neurogenesis was increased upon MSC transplantation, along with neuronal precursor cell differentiation in the SN [21] . Similar effects of MSC transplantation were seen on hippocampal neurogenesis [22] . Hence, neurogenic MSC effects might lead to memory improvements and therapeutic effects on olfactionthereby providing a promising regenerative therapy for nonmotor symptoms in PD.
Adipose tissue contains an abundant vascularization and therefore represents a rich resource of MSC that contains up to 500 times more MSC compared with bone marrow. Furthermore, adipose-derived MSC (AD-MSC) show higher proliferative capacity, later senescence and a higher level of neurotrophin secretion than bone-marrow-derived MSC [23] [24] [25] . Our group and others showed recently that AD-MSC improve motor deficits and partially restore dopaminergic marker expression in the striatum and SN [26, 27] , exert potent immunomodulation [28] and increase brain-derived neurotrophic factor (BDNF) and GFAP levels in the SN [27] of Parkinsonian rats. Furthermore, another short-term study from our lab showed increased neurogenesis upon AD-MSC transplantation in comparison to Parkinsonian rats without AD-MSC treatment [29] . Yet, there is a lack of long-term assessments to ensure the safety of nondifferentiated AD-MSC in the brain and to assess their differentiation and survival. One key issue for long-term studies remains the detection of MSC, given the lack of specific MSC markers that could ensure their tracking and the long-term safety for human applications [30] . Most studies only show human DNA detection [28] or observe a vanishing graft [22, [31] [32] [33] [34] [35] , hindering an assessment of MSC differentiation and development. Consequently, the current study aimed to assess long-term neurogenic, cognitive, immunomodulatory and neuroprotective effects of AD-MSC in respect to their detection, differentiation and homing following transplantation into 6-OHDA lesioned rats.
Materials & methods

Liposuction
After obtaining informed consent from the patient, collected according to the guidelines set by the Ethics Review Board of the Charité University Medicine Berlin, adipose tissue samples were obtained from a 21-year-old female patient during tumescent liposuction. During tumescent liposuction, saline containing anesthetic as well as epinephrine was infused into the subcutaneous tissue through one cannula and then both liquid and tissue were removed with suction.
Isolation & cultivation of AD-MSC
AD-MSC were isolated from adipose tissue by rinsing the tissue samples extensively with 0.1 M phosphatebuffered saline (PBS) containing no magnesium and no calcium ions (Biochrom AG, Berlin, Germany). The fat/ PBS suspension was centrifuged at 350 g for 5 min until three layers were obtained. After removing the upper oily layer and the lower aqueous phase, the fatty layer was extracted and digested for 60 min with 0.2 U/ ml collagenase NB4 (Serva Electrophoresis). Subsequently, the sample was centrifuged. The pellet was resuspended in 0.1 M PBS and filtered through a 70 μm strainer. Cells were seeded at a density of 1.6 × 10 5 cells/cm 2 in DMEM (low glucose; Gibco, UK) culture medium, containing 10% fetal calf serum (Biochrom AG), and 1% penicillin/streptomycin (Invitrogen, Life Technologies, UK).
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Transfection of AD-MSC
The Neon ™ Transfection System (Invitrogen) was used as the nonviral delivery of plasmid DNAs by electroporation. After passage 2, AD-MSC were harvested at 80-90% confluency and diluted in 'resuspension buffer R' (Invitrogen) to a final concentration of 1 × 10 7 cells/ml. For every transfection, 1 million AD-MSC/100 μl were combined with 4.5 μg of a Sleeping Beauty Transposon encoding the EGFP marker under control of a human elongation factor 1 alpha promoter, as well as SV40 promoter driving expression of a puromycin selection marker, as well as 0.5 μg of the Sleeping Beauty transposase expression vector SB100. Electroporation was set up according to the manufacturer's protocol, applying three pulses of 10 ms each at 1500 V. Afterward, AD-MSC were immediately transferred to standard culture medium. After 48 h, the medium was replaced with puromycin (3 μg/ml) containing medium for 7 days to select for cells with chromosomal integration of the transposon, in other words, green-fluorescent protein (GFP) expressing AD-MSC.
In vivo experimental design
To explore and characterize AD-MSC transplantation into hemiparkinsonian rats and their effects on neurogenesis and regeneration, adult male Wistar rats (n = 40) received 2 μl 6-OHDA or sodium chloride (NaCl) infusions (sham group) into the medial forebrain bundle. Six days after the lesioning, all rats were tested for motor behavior in the rotameter bowels. Seven days later, groups (n = 7/ group) received either 5 μl NaCl or 5 μl of AD-MSC ipsilateral infusions into the SN. Four experimental groups were obtained: sham lesioned animals that received intranigral NaCl injections, 6-OHDA lesioned animals that received intranigral NaCl injections, lesioned animals that received an intranigral injection of AD-MSC (Figure 1) . In order to choose the most ideal control group treatment, we based our decision on previous articles in the field [20] [21] 27, 34, [36] [37] that used NaCl or PBS, however this control group did not reflect the potential to control cell implantation-related impacts.
After AD-MSC or NaCl injections animals received 1 intra peritoneal (i.p.) 5-bromo-2-deoxyuridine (BrdU) injection (50 mg/kg) per day over a 3-day period and were tested again for motor behavior in the rotameter bowels after 4 weeks and a day before their perfusion after 6 months (Figure 1 ). To assess for memory impairments, the 8-arm maze was used 20 days after lesion induction.
Animals
Adult male Wistar rats were purchased from Harlan Winkelmann Laboratory. Animals were kept under standard housing conditions with a light/dark cycle of 12 h/12 h and with free access to food and water. The study was approved by the local ethic committee 'Landesamt für Gesundheit und Soziales,' Berlin. Suffering of rats was minimized and ameliorated with appropriate anesthetics future science group Research Article Schwerk, Altschüler, Roch et al.
6-OHDA lesioning
In order to achieve an end-stage PD model, the medial forebrain bundle was fully lesioned. Stereotaxic operations (David Kopf Instruments, Germany) were carried out under anesthesia with i.p. injections of pentobarbital (60 mg/kg, Sigma Aldrich, Germany). Dopaminergic lesioning was induced by a unilateral 2-point injection of 6.5 μg 6-OHDA (Sigma Aldrich) dissolved in 2 μl saline containing 0.1% ascorbic acid using a 26s gauge Hamilton microsyringe. The following bregma coordinates were chosen: tooth bar (TB): 
Quantification of endogenous neurogenesis in the SVZ & dentate gyrus
Total diaminobenzidine (DAB; Sigma Aldrich) BrdU in the SVZ (including the lateral wall of the ventricles) was quantified by counting one-in-six series, resulting in six coronal sections from the appearance of the third ventricle (1.70, anterior to bregma) to the disappearance of the anterior commissure (-0.4, posterior to bregma). Similarly, one-in-six series of DAB BrdU stained cells were counted in the SGZ and granule cell layer of the dentate gyrus (DG), resulting in eight sections per animal. Obtained numbers were then multiplied by 6 in order to estimate the total number of BrdU-immunoreactive cells.
Fluorescent staining of the SVZ was visualized and quantified with a confocal microscope (Leica TCS SP2) at 40× magnification. For each group (n = 5), 40-μm thick sections were stained and the total number of BrdU-positive cells (BrdU+) was counted. Double positive cells, for BrdU and HuD cells (BrdU+/ HuD+) were quantified to assess neurogenesis, and double positive cells for BrdU and S100β (BrdU+/ S100β+) were quantified to assess gliogenesis on each hemisphere in two subregions of the SVZ, the lateral ventricle and the beginning of the rostral migratory stream. BrdU+/ HuD+ and BrdU+/ S100β+ and total BrdU cell numbers were counted in every 6th section and selected regions were analyzed in sequential scanning mode. Ratios of double-labeled cells versus all BrdU+ cells are given.
Quantification of dopaminergic neurons
To verify the lesion, TH+ neurons were counted in the SN. Stereological cell counts of TH+ neurons in the SN were based on anatomical landmarks, as described in Tepper et al. [38] and according to Paxino and Watson [39] . To circumvent arbitrary delineation, the whole of the rostrocaudal extent of the SN (including the pars compacta, pars reticulata and pars lateralis) were counted using the 'Meander Scan' option and a semi-automated stereology system (StereoInvestigator, MicroBrightfield, VT, USA) employing a Leica DMRA microscope attached to a Retiga-2000R camera (QImaging, Canada). One-in-twelve series of 40 μm coronal sections were evaluated for each group (n = 7) resulting in four sections in total. The SN was delineated using the 5× objective, while counting was done at the 40× objective. All cell counts were executed by the same investigator in a blind manner. The coefficient of error (ranging between 0.05 and 0.1) without the estimation bias of the total numbers was calculated according to Gundersen and Jensen. For quantification, TH+ cell numbers were expressed as percentage of the nonlesioned side. The grid was determined manually based on the shape of the SN. The counting frame is determined automatically based on the grid size. For the counting of TH+ cells in the SN, four coronal sections of 40 μm were used per animal.
Quantification of inflammatory response
In order to determine the (peripheral) inflammatory response to the transplantation, all rat sera and conditioned media were analyzed for the presence of various cytokines, chemokines and growth factors, using multiplex assay kits and Luminex technology (BioSource/ Invitrogen, Germany). Rat sera were collected at the time of the perfusion. A rat 22-plex kit was designed to test for angiogenic (VEGF, monocyte chemoattractant protein-1) and hematopoietic cytokines/ chemokines (granulocyte colony-stimulating factor, granulocyte macrophage colony-stimulating factor, macrophage colony-stimulating factor, IL-5, IL-7) and for pro-(TNF-α, human growth-regulated oncogene/ keratinocyte chemoattractant, IFN-γ, IL-1α, IL1β, IL-12p70, IL-17α, IL-6, IL-18, regulated upon activation normal T-cell expressed and secreted, macrophage inflammatory protein-3α) and anti-inflammatory cytokines/chemokines (EPO, IL-10, IL-4, IL-13). All procedures were carried out according to the manufacturer's instruction. Briefly, 50 μl of undiluted serum was added to wells containing antibody coated beads and incubated for 2 h at room temperature. The beads future science group Adipose-derived MSC induce neuroprotective effects in the rat model for Parkinson's disease Research Article were washed and incubated with biotinylated detector antibody for 1 h, then washed again and incubated with streptadivin-RPE for 30 min. After another wash, fluorescence was detected using a Luminex-100 instrument and analyzed with proprietary software. The amount of each cytokine in picoG/ml was used for comparisons between groups. A highly specific cytokine kit was chosen that was tested negative for human cross-reactions.
Behavioral tests
Seven days before the start of the experiments, animals were handled for approximately 2 min daily. All experiments were carried out between 8:00 and 12:00 am. Before each trial, the radial maze and conditioning chamber were cleaned with water, and rotameter bowls were cleaned with water containing 30% ethanol. In order to reduce stress and novelty seeking behavior, animals were transported in their home cage and allowed to habituate for 30 min prior to the start of the experiments.
D-amphetamine-induced rotations
Rotational response to D-amphetamine is a classic functional measure of unilateral dopaminergic denervation [40] . One week post-lesion (day 8), 20 days postgrafting (day 29) and after 6 months, animal rotational behavior was tested in response to D-amphetamine sulfate injection (2725 mg/kg dissolved in 0.9% saline i.p., Sigma Aldrich). Animals were injected and placed into automated rotameter bowls (TSE Systems, Germany). The number of turns performed by the animals greater than 180° was recorded for 90 min starting 15 min after injection.
Eight-arm radial maze
The test was conducted according to a previous protocol [41] with slight modifications. The radial arm maze was constructed of dark gray polyvinylchloride and consisted of an octagonal center platform (50 cm in diameter) and eight equally spaced arms radiating from the octagon (42 cm long and 10 cm wide). A semicircular food cup, 3 cm in diameter and 1 cm deep, was located at the outer end of each arm in order to present a food reinforcer that is to say a quarter of a peanut. The apparatus was placed centrally on the floor of the experimental chamber which was uniformly and indirectly lit with 4 40W bulbs and had white walls. Furthermore, the experimental room was equipped with visible extra-maze cues that remained constant during the study to allow spatial orientation. Three days before the experiment, food deprivation was initiated and kept throughout the test. The rats were fed 2 h per day -with water ad libitum -in order to reduce their body weight to approximately 85% of the initial value. Body weight was monitored on a daily basis. During the first 2 days of the 8-day testing period, rats were habituated to the maze and trained to find the reinforcers. All arms were baited and animals were individually placed in the center of the maze for the duration of 10 min. In the course of the subsequent 6 days memory tasks were performed. During this test phase, only the arms, which were directed toward the extra cues, were baited with constant location between trials. The rats were free to explore the maze and remained on the maze either until all three rewards had been eaten or until 10 min had elapsed. The first entry into an unbaited arm was scored as reference memory error (RME), any arm re-entries (either in a formerly baited or unbaited arm) were scored as working memory error (WME). The test was conducted from day 21 to day 28 after the 6-OHDA lesion.
Statistical analyses
Data were presented as mean and standard error of the mean with the significance level set at p = 0.05. Group comparisons were analyzed with an analysis of variance (ANOVA), repeated measurements ANOVA (rmANOVA) and multivariate ANOVA (MANOVA), followed up with least significant difference (LSD) or Tamhanes posthoc comparisons using SPSS (IBM, version 22). In some tests (Multiplex and SVZ DAB BrdU analyses), data were transformed to the logarithm of the basis 10 (log10) to normalize the skewed distribution.
Results
AD-MSC secrete VEGF in vitro & increase peripheral EPO & Il-10 levels in vivo
Multiplexed analyses of 22 pro-and anti-inflammatory cytokines and chemokines were applied to all rat sera and to culture medium of AD-MSC. Only VEGF, a potent factor for the induction of vasculogenesis and angiogenesis, was found to be elevated in AD-MSC medium compared with unconditioned medium.
Serum analyses indicated that EPO levels were significantly different between groups [F (2, 22) = 6.55, p = 0.01, partial η 2 = 0.37]; posthoc comparisons showed significantly higher EPO levels in AD-MSC versus 6-OHDA (p = 0.002) and higher EPO levels in sham versus 6-OHDA (p = 0.02). Furthermore, log10 transformed IL-10 levels were significantly different between groups [F (2, 24) = 6.45, p = 0.006, partial η 2 = 0.35], LSD posthoc tests showed significant higher IL-10 levels in AD-MSC (p = 0.01) and sham (p = 0.01) as compared with 6-OHDA. Log10 transformed IL-2 levels were also found to be different between groups [F (2, 18) = 5.00, p = 0.02, Table 1 ). Indicating that both AD-MSC and sham transplanted animals had higher numbers of newly generated surviving neurons compared with 6-OHDA, while there was no difference between sham and AD-MSC. 
AD-MSC transplantation improves working memory in the radial-arm-maze test
When analyzing WME of the six trials, there was a significant main effect of WME [F (5, 21) = 8.79, p = 0.000, partial η 2 = 0.68], indicating learning of all groups. There was also a significant interaction of group membership and WME [F (10, 44) = 2.13, p = 0.04, partial η 2 = 0.33], which indicated that at the first test day, sham scored better than 6-OHDA (p = 0.005), and also at day 2 sham performed better than 6-OHDA (p = 0.006) and AD-MSC (p = 0.05), yet there was no difference at day 3. However, from day 4 onward AD-MSC showed fewer WME than 6-OHDA (day 4: p = 0.001; day 5: p = 0.000; day 6: p = 0.000) and sham animals showed also continuously a better performance than 6-OHDA (day 4: p = 0.000; day 5: p = 0.000; day 6: p = 0.000) ( Figure 10A , Table 2 ).
When analyzing RME, there was only a significant main effect of RME [F (5, 21) = 8.73, p = 0.000, partial η 2 = 0.68] indicating a learning effect for all groups. Taken together, these data show that all groups were able to improve their short-term and reference memory over time, yet the 6-OHDA group showed impairments in short-term memory (WME) as compared with both sham and AD-MSC groups -indicating that AD-MSC transplantation improved working memory performance in lesioned animals.
AD-MSC treatment does not improve motor function in PD animals
When comparing the rpm over the three test dates, rmANOVA showed no significant interaction between group and rotation test days (p = 0.85), and no difference across test days (p = 0.08), but a significant difference of treatment condition [F (2,23) = 4.89, p = 0.02, partial η 2 = 0.30), indicating that sham animals turned significantly less over the three test days compared with AD-MSC (p = 0.02) and 6-OHDA (p = 0.007) ( Figure 10B ).
Discussion
In the present study, viable AD-MSC descendants were detectable up to 6 months following intranigral transplantation in the 6-OHDA lesioned rat brain and exerted beneficial effects on adult neurogenesis in the SVZ and DG, memory function, TH-levels, and on peripheral cytokines. AD-MSC localized often around blood vessels or in the arachnoid mater -two microenvironments that provide a protective microenvironment for the survival and differentiation of resident and exogenous stem cells due to their stem cell niche-like characteristics [42] [43] [44] , and due to circulating growth factors [45, 46] . We assume that AD-MSC indeed increased the generation and survival of neurons in the dentate gyrus, considering that it was shown previously that 4 weeks after injecting BrdU into mice, the vast majority of BrdU+ cells express neuronal phenotype markers [47] . The increased hippocampal neurogenesis of AD-MSC treated versus nontreated Parkinsonian animals was functionally related with improved memory test performance, as shown by significantly less WME made by AD-MSC versus 6-OHDA animals. This is in line with prior studies showing working memory deficits upon 6-OHDA lesioning [48] . Cognitive decline is a main nonmotor symptom of PD [49] that predisposes the majority of patients to progress to dementia [50] , underlining the relevance of early neuroprotective and potentially disease-modifying treatment strategies.
Furthermore, not only hippocampal neurogenesis was increased but also also subventricular neurogenesis, characterized by BrdU+/ HuD+ neurons, was about 15% higher in AD-MSC treated animals compared with 6-OHDA lesioned untreated animals, while there was no difference between sham and AD-MSC, indicating a normalizing effect of AD-MSC treatment on subventricular neurogenesis. Similar results were found in our previously published short-term study, which showed higher neurogenesis in the SVZ of AD-MSC treated rats versus only 6-OHDA lesioned rats [29] . Both of these neurogenic zones show decreased numbers of neurons going along with α-synuclein positive inclusions in PD patients [4, 5] , which have been linked to dopaminergic denervation [4] . Furthermore, neuronal loss in the OB showed a strong correlation with disease duration in PD [5] , implicating a progressive degeneration of OB neurons. Hence therapeutic modulation of endogenous plasticity in the SVZ-OB axis with vehicles like AD-MSC might present a promising treatment strategy in PD that could help restore the OB and hippocampal neurogenesis, going along with hyposmia and cognitive decline. In line with previous studies [4] , we found a positive correlation between the amount of subventricular BrdU+/ HuD+ neurons and the amount of dopaminergic neurons in all groups, indicating a relationship of increased neurogenesis with increased dopaminergic tone. We assume not only an interaction of the transplanted AD-MSC with the local microenvironment inducing neuroprotection on one hand but also the generation of newborn neurons on the other hand, as shown in previous recent studies from our group. Furthermore, our colleagues showed a profound effect of AD-MSC on TH and BDNF levels and on motor behavior in Parkinsonian rats [27] . 
The protection of dopaminergic neurons in 6-OHDA lesioned animals following AD-MSC treatment might be supported by local microenvironmental changes, stimulated by altered cytokines levels and growth factors, as IL-10, whose transgenic expression was shown to protect TH levels in the SN and in the striatum of 6-OHDA lesioned rats [51] . Yet, there was still no complete histological recovery in our study, which might have caused the lack of motoric amelioration that was measured with rotational performances. Furthermore, our results suggest that AD-MSC transplantation affects cognition and anti-inflammatory parameters that eventually lead to neuroprotection, rather than motor behaviour. However, the outcomes of the rotational performances must be interpreted with caution, as they reflect only few Parkinsonian symptoms in the 6-OHDA model and as they show low external validity [52, 53] . In addition, there is no linear correlation of rotational performances and dopamine loss or recovery of dopamine [54] . This raises the possibility that rotometry might not cover the amelioration achieved by AD-MSC and suggests that upcoming studies should employ a battery of motor behavior test or employ more sensitive motoric tests [53] . Another limitation encountered in our study design was the lack of an appropriate control group that reflects any potential cell implantation-related impact, for example, nontrophic factor secreting fibroblasts. Therefore, future studies should address this requirement with more rigors.
In the present study, several cytokines/chemokines were found to be decreased by 6-OHDA, while there were similar in AD-MSC and sham lesioned animals, indicating a normalizing effect of AD-MSC treatment. Yet, higher IL-10, IL-4 and IL-2 are also elevated in allograft reactions, considering that we found viable and functionally intact MSC, with similar cytokine levels as sham, we do not assume that the elevation is due to an allograft reaction. Rather we found that AD-MSC significantly increased factors related to the modulation of neurogenesis, leading to similar cytokine levels as measured in sham treated controls. EPO -a growth factor for hematopoietic progenitor cells -has been shown to lead to antiapoptotic, antioxidant and anti-inflammatory effects on neurons, glial and endothelial cells and to stimulate angiogenesis and neurogenesis and the migration of neuroblasts [55, 56] . Also, the anti-inflammatory IL-10, known to modulate adult neurogenesis [57, 58] , was elevated upon AD-MSC transplantation. The stimulation of these exemplary factors supports the hypothesis of AD-MSC-induced neurogenesis through changes in the local microenvironment of the lesioned brain and show in general, as a proof of principle, that the microenvironment in the Parkinsonian brain is modulated by AD-MSC, with resulting neurogenic and neuroprotective effects.
The demonstrated neurogenic and neuroprotective effects of AD-MSC in our study might also be supported by their in vivo BDNF expression, which has a well-known role in supporting neurogenesis and providing trophic supply to dopaminergic neurons. After transplantation, AD-MSC were rather characterized by the expression of neurotrophic (BDNF), pericytical (NG2, CD34) and endothelial markers (von Willebrandt Faktor), eventually indicating a fusion with other endogenous cells, as it has been shown previously [59, 60] . This fact also might lead to false absolute numbers of AD-MSC surviving in the brain over a long period of time, so in this study qualitative but no absolute quantitative characterization of AD-MSC was provided. Furthermore, AD-MSC localized predominantly in the arachnoid mater, which contains trophic factors [42, 61] and might function as a stem-cell niche [42, [62] [63] supporting stem/precursor cell migration and distribution [64] . Therefore, it could be suggested that the arachnoid mater localization of AD-MSC supported or even enabled their long-term survival.
A progressive decrease or even a complete disappearance of MSC grafts is seen frequently in rat models [22, [31] [32] [33] [34] [35] , making long-term analyses difficult to validate. Regarding genetically engineered MSC, one of the underlying factors contributing to disappearing grafts might be a decrease in transgene expression. We showed previously that human specific marker give reliable and valid staining results by robust costaining with GFP, yet shortly after transplantation some AD-MSC stopped expressing GFP, but remained positive for human markers [29] . Gene silencing has been shown repeatedly in adult stem cells [65] [66] [67] . Consequently, additional human markers are essential to reliably track MSC. Our study used three different human specific markers to verify true AD-MSC survival and phenotyping. The fact that all AD-MSC stopped expressing GFP in vivo but not in vitro most likely reflects changes in the epigenetic state of the transgene, corresponding to their remarkable remodeling capacity that is indicated by their apparent microenvironmentally dependent transdifferentiation potential. Nevertheless, we were able to detect the AD-MSC 6 months after transplantation, but could not provide a reliable quantification of the cells at certain time points or the decrease in absolute numbers of AD-MSC over time, hence a correlation of the changing numbers of Adipose-derived MSC induce neuroprotective effects in the rat model for Parkinson's disease Research Article AD-MSC over time with the described histological and behavioral effects remain speculative. In sum, our results showed that AD-MSC transplantation -which could be tracked over a long-term period of 6 months -leads to improvements on cognitive performance, increased TH levels, subventricular and hippocampal neurogenesis and increased the content of anti-inflammatory factors. This suggests a neuroprotective effect of AD-MSC in PD models, along with the potential of inducing endogenous repair programs in both neurogenic niches of the adult brain, potentially leading to improvements in nonmotor symptoms of PD, which affect patients early and hence represent a potential disease-modifying target.
Future perspective
The detection of adult MSC in 1970 [68] has brought a lot of new insights and new ways of application of adult stem cells. Not only their autologous potential and their ease of extraction and expansion have gained a lot of interest by colleagues in the field; primarily their profound effects on immunomodulation and their capacity to home toward injured structures without the risk of teratoma formation or other carcinogenic properties, have made these adult stem cells a very promising application for many types of diseases, including multiple sclerosis, chronic Graft Versus Host Disease and PD. The homing capacity of MSC also predisposes these cells as ideal vehicles for targeted vector delivery, for example, for delivering neurotrophic factors or other proteins of interest. Yet, how MSC are migrating in pathological and physiological states is still elusive and will be a very exciting topic in the next years [69] , starting with the exploration of chemotactic pathways and interactions of MSC with the microenvironment.
Another aspects that will probably be examined in more detail in the near future are alternative routes of MSC application. As shown by many studies, MSC are able to migrate, and hence might be able to pass the blood-brain barrier (BBB) when aided by other concomitantly infused compounds to open that barrier, for example, via receptor-mediated endocytosis/ transcytosis [70] . Consequently, invasive procedures to apply these cells could be exchanged by more uncomplicated ways of application, once the mechanisms of MSC migration are better understood and can be guided more easily, for example, by the use of chemotaxis or by opening the BBB. Consequently, the amount of infused cells can be reduced if studies will use more tailored MSC that are designed for specific tissues and contexts. A combination of all these techniques would be ideal, for example, designing a chemotactic route for MSC, and -in the case of systemic administration -temporarily opening the BBB to allow a high infiltration into cerebral target structures. Furthermore, during the next 5-10 years, there will be more information on the in vivo microenvironment, anatomic location and phenotype of MSC, elucidating their mechanisms of migration and their biological function, which will enable new approaches that intend to mobilize endogenous MSC in conditions of disease or neurodegeneration. In addition, understanding the biological functions of MSC could greatly help in tailoring cell therapies [71] . In line with this, the understanding of MSC biology will shift more away from progenitor functions and will be more defined to MSC paracrine and immune modulation effects. Comprehending the precise contexts of MSC regulation could greatly help to exploit MSC benefits, (1) † Indicating significant differences between sham control vs 6-OHDA. ‡ Indicating significant differences between AD-MSC vs sham control. § Indicating significant differences between AD-MSC vs 6-OHDA. 6-OHDA: 6-Hydroxydopamine; AD-MSC: Adipose-derived mesenchymal stem cells; WME: Working memory errors.
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Hence, future studies will focus on improved therapeutic delivery methods of MSC, exploiting their biological functions and their chemotaxis to achieve safe ways of therapy. Furthermore, we anticipate that AD-MSC will gain more and more interest in the next 5-10 years, given their abundance, convenient isolation and cultivation, and their higher proliferative capacity, later senescence, and higher neurotrophin secretion than bone-marrow-derived MSC [23] [24] [25] [72] [73] [74] , making them the focus of most current MSC research. No writing assistance was utilized in the production of this manuscript.
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Executive summary
Background
• Adipose-derived mesenchymal stem cells (AD-MSC) have been shown to be neuroprotective and might represent a new treatment approach in Parkinson's disease, yet, long-term results are missing.
Methods
• AD-MSC were transplanted into 6-hydroxydopamine lesioned rats and their effects were evaluated after 6 months.
Results
• AD-MSC survived up to 6 months in the lesioned substantia nigra and localized often in the arachnoid mater surrounding the brain and around blood vessel luminae.
• AD-MSC protected dopaminergic neurons, upregulated anti-inflammatory cytokines, and boosted neurogenesis and memory.
• The percent of dopaminergic neurons correlated positively with newly generated surviving neurons of the subventricular zone in all groups, indicating a relationship between the amount of dopaminergic neurons and subventricular neurogenesis.
Discussion
• AD-MSC could exert disease-modifying effects in Parkinson's disease, due to their modulatory effects on both adult neurogenic zones, while also protecting dopaminergic neurons.
